Drug Trial Radar · NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
370
Planned (sponsor's estimate)
Start
Jan 30, 2026
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Summit Therapeutics
- First posted
- Feb 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Conditions
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Non-small Cell Lung Cancer (NSCLC)
- NSCLC
- Colorectal Cancer (CRC)
- CRC
Interventions
DaraxonrasibDrug
oral tablets
ElironrasibDrug
oral tablets
ZoldonrasibDrug
oral tablets
IvonescimabDrug
IV infusion
Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)Drug
IV infusion
cetuximab (Cohort C2 Only)Drug
IV infusion
Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)Drug
IV infusion
Daraxonrasib (Cohort B1 only)Drug
oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events (AEs)Time frame: Up to approximately 4 years
- Changes in vital signsTime frame: Up to approximately 4 years
- Changes in clinical laboratory test valuesTime frame: Up to approximately 4 years
- Dose Limiting ToxicitiesTime frame: 28 days
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut · Recruiting
University of Kentucky HealthCare (UK HealthCare)
Lexington, Kentucky · Recruiting
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
The Jame Outpatient Care West Campus
Columbus, Ohio · Recruiting
OHSU Knight Cancer Institute
Portland, Oregon · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.